Karyopharm Therapeutics reported Q2 revenue of $33.43 million, beating estimates thanks to strong sales of its cancer drug XPOVIO®. However, the company missed EPS expectations with a loss of $2.32 per share and faces financial challenges including negative debt-to-equity and cash flow ratios. Karyopharm is shifting focus to its Myelofibrosis program and advancing its Selinexor drug, maintaining its full-year revenue guidance of $130-$150 million.
Dogecoin has surged above the $0.10 mark for the first time since early June, supported by a 72% increase in derivatives trading volume and growing open interest reaching $1.66 billion. Spot Dogecoin ETFs in the U.S. saw net inflows of nearly $910,00...
NEAR Protocol has partnered with Ondo Finance to offer tokenized versions of 20 U.S. equities, ETFs, and commodity-backed instruments on the near.com platform. This allows qualified participants to buy and trade shares of major companies like Tesla, ...
Zephyr Energy reported a 45% year-on-year increase in second-quarter production from its non-operated US portfolio, averaging 914 barrels of oil equivalent per day, surpassing management forecasts. Oil made up 69% of production, and strong commodity ...
Solana is advancing its Alpenglow consensus upgrade to the public testnet stage, aiming to reduce transaction finality time from about 13 seconds to roughly 150 milliseconds. This upgrade replaces the current TowerBFT consensus with a new protocol ca...
Zcash surged about 10% to over $1,600, outperforming major cryptocurrencies while Bitcoin stabilized near $87,000 following recent gains. The broader crypto market benefited from declining oil prices and Treasury yields, boosting investor confidence ...
